Brought to you by 
Triton BioSystems gets rights to Xoma's ING-1 MAb
19 Apr 2021
Executive Summary
Triton BioSystems (therapeutics that use heat to treat cancer) has received exclusive worldwide rights to combine Xoma's (antibody and protein-based therapeutics) anti-tumor Human Engineered ING-1 monoclonal antibody with its preclinical Targeted Nano-Therapeutics (TNT) system to treat breast, colorectal, lung, ovary, and prostate cancers.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Triton BioSystems gets rights to Xoma's ING-1 MAb
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice